Kefeng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kefeng Wang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Bin Wu
Department of Urology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
3 shared publicationsXiaonan Chen
Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
2 shared publicationsYiqiao Zhao
Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
2 shared publicationsZijia Tao
Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
2 shared publications- Binghua Tan
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication - Duoguang Wu
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication
Latest Publications
- 1 June 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (16_suppl) , e16030
Artificial intelligence model for predicting the efficacy of sintilimab plus chemotherapy in treating patients with esophageal squamous cell carcinoma.
- 1 June 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (16_suppl) , e16030
Artificial intelligence model for predicting the efficacy of sintilimab plus chemotherapy in treating patients with esophageal squamous cell carcinoma.
- Open Access
Coffee consumption and risk of prostate cancer: a systematic review and meta-analysis
Objectives: To conduct a systematic review with meta-analysis of cohort studies to evaluate the association of coffee consumption with the risk of prostate cancer.Data sources: PubMed, Web of Science and Embase were searched for eligible studies up to September 2020.Study selection: Cohort studies were included.Data extraction and synthesis: Two researchers independently reviewed the studies and extracted the data. Data synthesis was performed via systematic review and meta-analysis of eligible cohort studies. Meta-analysis was performed with the “metan” and “glst” commands in Stata 14.0.Main outcomes and measures: Prostate cancer was the main outcome. It was classified as localised prostate cancer which included localised or non-aggressive cancers; advanced prostate cancer which included advanced or aggressive cancers; or fatal prostate cancer which included fatal/lethal cancers or prostate cancer-specific deaths.Results: Sixteen prospective cohort studies were finally included, with 57 732 cases of prostate cancer and 1 081 586 total cohort members. Higher coffee consumption was significantly associated with a lower risk of prostate cancer. Compared with the lowest category of coffee consumption, the pooled relative risk (RR) was 0.91 (95% CI 0.84 to 0.98), I2= 53.2%) for the highest category of coffee consumption. There was a significant linear trend for the association (p=0.006 for linear trend), with a pooled RR of 0.988 (95% CI 0.981 to 0.995) for each increment of one cup of coffee per day. For localised, advanced and fatal prostate cancer, the pooled RRs were 0.93 (95% CI 0.87 to 0.99), 0.88 (95% CI 0.71 to 1.09) and 0.84 (95% CI 0.66 to 1.08), respectively. No evidence of publication bias was indicated in this meta-analysis.Conclusions: This study suggests that a higher intake of coffee may be associated with a lower risk of prostate cancer.
Open AccessCoffee consumption and risk of prostate cancer: a systematic review and meta-analysis
Objectives: To conduct a systematic review with meta-analysis of cohort studies to evaluate the association of coffee consumption with the risk of prostate cancer.Data sources: PubMed, Web of Science and Embase were searched for eligible studies up to September 2020.Study selection: Cohort studies were included.Data extraction and synthesis: Two researchers independently reviewed the studies and extracted the data. Data synthesis was performed via systematic review and meta-analysis of eligible cohort studies. Meta-analysis was performed with the “metan” and “glst” commands in Stata 14.0.Main outcomes and measures: Prostate cancer was the main outcome. It was classified as localised prostate cancer which included localised or non-aggressive cancers; advanced prostate cancer which included advanced or aggressive cancers; or fatal prostate cancer which included fatal/lethal cancers or prostate cancer-specific deaths.Results: Sixteen prospective cohort studies were finally included, with 57 732 cases of prostate cancer and 1 081 586 total cohort members. Higher coffee consumption was significantly associated with a lower risk of prostate cancer. Compared with the lowest category of coffee consumption, the pooled relative risk (RR) was 0.91 (95% CI 0.84 to 0.98), I2= 53.2%) for the highest category of coffee consumption. There was a significant linear trend for the association (p=0.006 for linear trend), with a pooled RR of 0.988 (95% CI 0.981 to 0.995) for each increment of one cup of coffee per day. For localised, advanced and fatal prostate cancer, the pooled RRs were 0.93 (95% CI 0.87 to 0.99), 0.88 (95% CI 0.71 to 1.09) and 0.84 (95% CI 0.66 to 1.08), respectively. No evidence of publication bias was indicated in this meta-analysis.Conclusions: This study suggests that a higher intake of coffee may be associated with a lower risk of prostate cancer.
- Open Access
- 28 February 2020
- Published by Springer Nature in Research Square
Coffee consumption is associated with a lower risk of prostate cancer: a meta-analysis
Background Although in vitro and in vivo experiments have suggested that coffee may exert inhibitory effects on prostate carcinogenesis, epidemiological studies have reported inconsistent results on the association between coffee consumption and prostate cancer. Methods We conducted a meta-analysis of cohort studies to assess the association between coffee consumption and prostate cancer risk. PubMed and Embase were searched for eligible studies up to Jan 2020. Study-specific risk estimates were combined using fixed or random effects models depending on whether significant heterogeneity was detected. Results Fifteen prospective cohort studies, with 50,200 cases of prostate cancer and 949,752 total cohort members, were included in the meta-analysis. A statistically significant inverse association was detected between coffee consumption and prostate cancer risk. The pooled relative risk (RR) was 0.91 (95% CI: 0.84, 0.98; I 2= 53.2%) for the highest coffee consumption compared with lowest consumption. The association exhibited a linear trend ( P =0.006 for linear trend), and the pooled RR was 0.989 (95% CI: 0.982, 0.997) for an increase of 1 cup of coffee per day. The pooled RRs were 0.93 (95% CI: 0.87, 0.99), 0.88 (95% CI: 0.71, 1.09) and 0.84 (95% CI: 0.66, 1.08) for localized, advanced and fatal prostate cancer, respectively. No publication bias was detected. Conclusions Our findings provide more evidence that increased coffee consumption is associated with lower prostate cancer risk. It implies that men might be encouraged to increase the coffee intake to lower their risk of prostate cancer.
- 28 February 2020
- Published by Springer Nature in Research Square
Open AccessCoffee consumption is associated with a lower risk of prostate cancer: a meta-analysis
Background Although in vitro and in vivo experiments have suggested that coffee may exert inhibitory effects on prostate carcinogenesis, epidemiological studies have reported inconsistent results on the association between coffee consumption and prostate cancer. Methods We conducted a meta-analysis of cohort studies to assess the association between coffee consumption and prostate cancer risk. PubMed and Embase were searched for eligible studies up to Jan 2020. Study-specific risk estimates were combined using fixed or random effects models depending on whether significant heterogeneity was detected. Results Fifteen prospective cohort studies, with 50,200 cases of prostate cancer and 949,752 total cohort members, were included in the meta-analysis. A statistically significant inverse association was detected between coffee consumption and prostate cancer risk. The pooled relative risk (RR) was 0.91 (95% CI: 0.84, 0.98; I 2= 53.2%) for the highest coffee consumption compared with lowest consumption. The association exhibited a linear trend ( P =0.006 for linear trend), and the pooled RR was 0.989 (95% CI: 0.982, 0.997) for an increase of 1 cup of coffee per day. The pooled RRs were 0.93 (95% CI: 0.87, 0.99), 0.88 (95% CI: 0.71, 1.09) and 0.84 (95% CI: 0.66, 1.08) for localized, advanced and fatal prostate cancer, respectively. No publication bias was detected. Conclusions Our findings provide more evidence that increased coffee consumption is associated with lower prostate cancer risk. It implies that men might be encouraged to increase the coffee intake to lower their risk of prostate cancer.
- Open Access
- 12 June 2016
- Published by Wiley in Cancer Medicine
- Vol. 5 (8) , 1856-1862
Downregulation of miR‐133b predict progression and poor prognosis in patients with urothelial carcinoma of bladder
We found microRNA‐133b (miR‐133b) was downregulated in urothelial carcinoma of the bladder (UCB) tissues, and it could inhibit the proliferation and induce apoptosis in UCB cells. Consequently, we intend to explore the clinical significance of miR‐133b in UCB patients. Expression of miR‐133b in 146 UCB specimens and matched adjacent non‐neoplastic bladder tissues were measured by quantitative real‐time polymerase chain reaction. The overall survival (OS) curve and progression‐free survival (PFS) curve were plotted using the Kaplan–Meier method. Prognostic factors for OS and PFS were identified by univariate and multivariate analyses using the Cox proportional hazards regression model. The expression of miR‐133b was significantly downregulated in UCB tissues compared with those in adjacent non‐neoplastic bladder tissues (P < 0.001). Among UCB patients, low expression of miR‐133b significantly correlated with aggressive clinicopathological features. Multivariate analysis indicated that the expression of miR‐133b was the independent prognostic factors for predicting PFS (RR: 2.97; 95% CI: 1.78–6.44; P = 0.009) and OS (RR: 4.23; 95% CI: 1.51–11.8; P = 0.011) in patients with UCB. Our study demonstrated that downregulation of miR‐133b associated with aggressive clinicopathological features and predicted unfavorable prognosis in patients with UCB, might serve as feasible biomarker for clinical outcome of UCB patients after surgery and potential therapeutic target in the future.
- 12 June 2016
- Published by Wiley in Cancer Medicine
- Vol. 5 (8) , 1856-1862
Open AccessDownregulation of miR‐133b predict progression and poor prognosis in patients with urothelial carcinoma of bladder
We found microRNA‐133b (miR‐133b) was downregulated in urothelial carcinoma of the bladder (UCB) tissues, and it could inhibit the proliferation and induce apoptosis in UCB cells. Consequently, we intend to explore the clinical significance of miR‐133b in UCB patients. Expression of miR‐133b in 146 UCB specimens and matched adjacent non‐neoplastic bladder tissues were measured by quantitative real‐time polymerase chain reaction. The overall survival (OS) curve and progression‐free survival (PFS) curve were plotted using the Kaplan–Meier method. Prognostic factors for OS and PFS were identified by univariate and multivariate analyses using the Cox proportional hazards regression model. The expression of miR‐133b was significantly downregulated in UCB tissues compared with those in adjacent non‐neoplastic bladder tissues (P < 0.001). Among UCB patients, low expression of miR‐133b significantly correlated with aggressive clinicopathological features. Multivariate analysis indicated that the expression of miR‐133b was the independent prognostic factors for predicting PFS (RR: 2.97; 95% CI: 1.78–6.44; P = 0.009) and OS (RR: 4.23; 95% CI: 1.51–11.8; P = 0.011) in patients with UCB. Our study demonstrated that downregulation of miR‐133b associated with aggressive clinicopathological features and predicted unfavorable prognosis in patients with UCB, might serve as feasible biomarker for clinical outcome of UCB patients after surgery and potential therapeutic target in the future.
- 17 August 2014
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 29 (5) , 370-374
In Vivo Evaluation of Chemical Composition of Eight Types of Urinary Calculi Using Spiral Computerized Tomography in a Chinese Population
This study was conducted to evaluate the chemical composition of eight types of urinary calculi using spiral computerized tomography (CT) in vivo. From October 2011 to February 2013, upper urinary tract calculi were obtained from 122 patients in the department of urinary surgery of the First Affiliated Hospital of Soochow University. All patients were scanned with a 64-detector row helical CT scanner using 6.50 mm collimation before ureterorenoscopy. Data from the preoperative spiral CT scans and postoperative chemical composition of urinary calculi were collected. The chemical composition analysis indicates that there were five types of pure calculi and three types of mixed calculi, including 39 calcium oxalate calculi, 12 calcium phosphate calculi, 10 calcium carbonate calculi, 8 magnesium ammonium phosphate calculi, 6 carbonated apatite, 21 uric acid/ammonium urate calculi, 10 uric acid/calcium oxalate calculi, and 16 calcium oxalate/calcium phosphate calculi. There were significant differences in the mean CT values among the five types of pure calculi (P < 0.001). Furthermore, we also observed significant differences in the mean CT values among three types of mixed calculi (P < 0.001). Significant differences in the mean CT values were also found among eight types of urinary calculi (P < 0.001). However, no statistically significant difference was observed between the mean CT values of magnesium ammonium phosphate calculi and uric acid/calcium oxalate calculi (P = 0.262). Our findings suggest that spiral CT could be a promising tool for determining the chemical composition of upper urinary tract calculi.
- 17 August 2014
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 29 (5) , 370-374
In Vivo Evaluation of Chemical Composition of Eight Types of Urinary Calculi Using Spiral Computerized Tomography in a Chinese Population
This study was conducted to evaluate the chemical composition of eight types of urinary calculi using spiral computerized tomography (CT) in vivo. From October 2011 to February 2013, upper urinary tract calculi were obtained from 122 patients in the department of urinary surgery of the First Affiliated Hospital of Soochow University. All patients were scanned with a 64-detector row helical CT scanner using 6.50 mm collimation before ureterorenoscopy. Data from the preoperative spiral CT scans and postoperative chemical composition of urinary calculi were collected. The chemical composition analysis indicates that there were five types of pure calculi and three types of mixed calculi, including 39 calcium oxalate calculi, 12 calcium phosphate calculi, 10 calcium carbonate calculi, 8 magnesium ammonium phosphate calculi, 6 carbonated apatite, 21 uric acid/ammonium urate calculi, 10 uric acid/calcium oxalate calculi, and 16 calcium oxalate/calcium phosphate calculi. There were significant differences in the mean CT values among the five types of pure calculi (P < 0.001). Furthermore, we also observed significant differences in the mean CT values among three types of mixed calculi (P < 0.001). Significant differences in the mean CT values were also found among eight types of urinary calculi (P < 0.001). However, no statistically significant difference was observed between the mean CT values of magnesium ammonium phosphate calculi and uric acid/calcium oxalate calculi (P = 0.262). Our findings suggest that spiral CT could be a promising tool for determining the chemical composition of upper urinary tract calculi.
- 1 August 2008
- Vol. 14 (8) , 740-2
[Fatty acid synthase and prostate cancer].
The over expression of fatty acid synthase (FAS), a key enzyme in biosynthesis of fatty acid, can enhance enzyme activity and result in the malignant behavior, special material metabolism and energy metabolism of tumors. The expression of FAS is significantly higher in prostate cancer than in normal prostate tissues, which shows that FAS can be used as a marker in the early diagnosis of prostate cancer. The abnormally increased expression of FAS in prostate cancer may offer a new target for the drug treatment of the disease.
- 1 August 2008
- Vol. 14 (8) , 740-2
[Fatty acid synthase and prostate cancer].
The over expression of fatty acid synthase (FAS), a key enzyme in biosynthesis of fatty acid, can enhance enzyme activity and result in the malignant behavior, special material metabolism and energy metabolism of tumors. The expression of FAS is significantly higher in prostate cancer than in normal prostate tissues, which shows that FAS can be used as a marker in the early diagnosis of prostate cancer. The abnormally increased expression of FAS in prostate cancer may offer a new target for the drug treatment of the disease.
- 1 July 2007
- Vol. 13 (7) , 617-9
[Adult prostate sarcoma: a report of 6 cases with clinical analysis].
To investigate the diagnosis, treatment and prognosis of sarcoma of the adult prostate. We reported 6 cases of sarcoma of the adult prostate, of which 3 were leiomyosarcoma, 2 rhabdomyosarcoma and 1 malignant neurilemoma, 2 at Ghavimi Stage II, 3 at Stage III and 1 at Stage IV. The patients were aged from 18 to 44 years (mean 31 years) and their disease course ranged from 3 to 12 months (mean 7 months). Five of them received operation, radiotherapy and / or chemotherapy and 1 underwent cystostomy only. Immunohistochemical dyeing showed vimentin to be positive while PSA and PAP negative in all the 6 cases, actin (HHF35) positive in the cases of leiomyosarcoma and rhabdomyosarcoma, and S-100 and lysozyme positive in the case of malignant neurilemoma. One case failed to be followed up, and the other 5 died 2-11 months after the operation. Sarcoma of the adult prostate initiates with the symptom of progressive dysuria, which can be diagnosed by DRE test and confirmed by needle biopsy. Early diagnosis and radical surgical resection may offer the best chance of survival, but with poor prognosis.
- 1 July 2007
- Vol. 13 (7) , 617-9
[Adult prostate sarcoma: a report of 6 cases with clinical analysis].
To investigate the diagnosis, treatment and prognosis of sarcoma of the adult prostate. We reported 6 cases of sarcoma of the adult prostate, of which 3 were leiomyosarcoma, 2 rhabdomyosarcoma and 1 malignant neurilemoma, 2 at Ghavimi Stage II, 3 at Stage III and 1 at Stage IV. The patients were aged from 18 to 44 years (mean 31 years) and their disease course ranged from 3 to 12 months (mean 7 months). Five of them received operation, radiotherapy and / or chemotherapy and 1 underwent cystostomy only. Immunohistochemical dyeing showed vimentin to be positive while PSA and PAP negative in all the 6 cases, actin (HHF35) positive in the cases of leiomyosarcoma and rhabdomyosarcoma, and S-100 and lysozyme positive in the case of malignant neurilemoma. One case failed to be followed up, and the other 5 died 2-11 months after the operation. Sarcoma of the adult prostate initiates with the symptom of progressive dysuria, which can be diagnosed by DRE test and confirmed by needle biopsy. Early diagnosis and radical surgical resection may offer the best chance of survival, but with poor prognosis.